Gadopiclenol in Contrast Enhanced MRI of the Prostate

Summary

The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.

Timeline

Start

2024-02-14

Primary completion

2027-02-01

Completion

2028-02-01

Drugs

Indications